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The importance of the immune system in pro-
tection against cancer was originally proposed 
in the theory of cancer immunosurveillance. 
This theory holds that the immune system can 
recognize cancerous cells as they arise and can 
mount both innate and adaptive immune re-
sponses to eliminate them. In support of cancer 
immunosurveillance is the fact that both im-
munodeficient or immunosuppressed patients 
and experimental animals are more susceptible 
to tumor development (for reviews see Dunn 
et al., 2004; Zitvogel et al., 2006; Swann and 
Smyth, 2007). Counter to the role of the immune   
system in staving off cancer is the ability of tu-
mors to escape the immune system by engen-
dering a state of immunosuppression (for review 
see Zitvogel et al., 2006). One example of a 
mechanism of immunosuppression present in 
tumor-bearing hosts is the promotion of T cell 
dysfunction or exhaustion.
T cell exhaustion describes a state of  T cell 
dysfunction that was initially observed dur-
ing chronic lymphocytic choriomeningitis virus 
(LCMV) infection in mice (Zajac et al., 1998). 
Exhausted T cells fail to proliferate and exert 
effector  functions  such  as  cytotoxicity  and   
cytokine secretion in response to antigen stim-
ulation. Further studies identified that exhausted 
T cells are characterized by sustained expression 
of the inhibitory molecule PD-1 (programmed 
cell death 1) and that blockade of PD-1 and   
PD-L1 (PD-1 ligand) interactions can reverse 
T cell exhaustion and restore antigen-specific 
T cell responses in LCMV-infected mice (Barber   
et al., 2006). T cell exhaustion also occurs dur-
ing chronic infections in humans (for review 
see Klenerman and Hill, 2005). CD8+ T cells in   
humans chronically infected with HIV (Day   
et al., 2006; Petrovas et al., 2006; Trautmann   
et al., 2006), hepatitis B virus (Boettler et al., 
2006), and hepatitis C virus (HCV; Urbani et al., 
2006) express high levels of PD-1, and block-
ing of PD-1–PD-L interactions can restore T 
cell function in vitro.
Several lines of evidence also implicate the 
PD-1–PD-L pathway in T cell exhaustion in 
cancer. First, PD-1 expression is found on tumor- 
infiltrating CD8+ T cells in multiple solid tumors 
(Blank et al., 2006; Ahmadzadeh et al., 2009;   
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The immune response plays an important role in staving off cancer; however, mechanisms 
of immunosuppression hinder productive anti-tumor immunity. T cell dysfunction or  
exhaustion in tumor-bearing hosts is one such mechanism. PD-1 has been identified as  
a marker of exhausted T cells in chronic disease states, and blockade of PD-1–PD-1L  
interactions has been shown to partially restore T cell function. We have found that T cell 
immunoglobulin mucin (Tim) 3 is expressed on CD8+ tumor-infiltrating lymphocytes (TILs) 
in mice bearing solid tumors. All Tim-3+ TILs coexpress PD-1, and Tim-3+PD-1+ TILs repre-
sent the predominant fraction of T cells infiltrating tumors. Tim-3+PD-1+ TILs exhibit the 
most severe exhausted phenotype as defined by failure to proliferate and produce IL-2, 
TNF, and IFN-. We further find that combined targeting of the Tim-3 and PD-1 pathways 
is more effective in controlling tumor growth than targeting either pathway alone.
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tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
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Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
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TIM-3 and PD-1 mark distinct populations of exhausted cells, 
with cells positive for both PD-1 and TIM-3 comprising the 
smallest fraction (Jones et al., 2008) of CD8+ T cells. Similarly,   
another group has shown that TIM-3 is up-regulated on ex-
hausted T cells in patients with HCV (Golden-Mason et al., 
2009). In this case, cells that coexpress TIM-3 and PD-1 are the 
most abundant fraction among HCV-specific CD8+ T cells.   
In both studies, blocking TIM-3 restored T cell proliferation 
and enhanced cytokine production.
Because targeting the PD-1–PD-L pathway alone does not 
result in complete restoration of T cell function (Blackburn   
et al., 2008), and in some cancers targeting the PD-1–PD-L 
pathway does not restore T cell function at all (Gehring et al., 
2009), there is a need to identify other molecules and inhibitory 
pathways that are involved in T cell exhaustion. Indeed, one 
study has identified LAG-3 as being expressed on exhausted   
T cells, and although treatment with anti–LAG-3 alone did 
not restore T cell function in LCMV-infected mice, it syner-
gized with PD-1 blockade to improve T cell responses and re-
duce viral load (Blackburn et al., 2009). Unfortunately, this study 
did not identify whether LAG-3 and PD-1 are expressed on dis-
tinct or overlapping populations of exhausted T cells. Given 
these observations, it appears that targeting multiple pathways 
may prove most effective in reversing T cell exhaustion.
We report in this paper the coexpression of Tim-3 and 
PD-1 on a large fraction of tumor-infiltrating lymphocytes 
Gehring et al., 2009) and on antigen-specific CD8+ T cells in 
hosts with nonsolid tumors (Yamamoto et al., 2008; Mumprecht 
et al., 2009). Second, these PD-1+ T cells are dysfunctional. 
Third, PD-L1 is expressed at high levels in several different 
cancers (Latchman et al., 2001; Dong et al., 2002; Brown et al., 
2003), and high expression of PD-L1 on tumors is strongly 
associated  with  poor  prognosis  (Thompson  et  al.,  2006). 
Fourth, interference with PD-1–PD-L signaling, either through 
antibody blockade or PD-1 deficiency, has been shown to 
improve clinical outcome and restore functional T cell re-
sponses in several cancers (Blank et al., 2006; Yamamoto et al., 
2008; Mumprecht et al., 2009; Zhang et al., 2009). However, 
targeting the PD-1–PD-L1 pathway does not always result in 
reversal of T cell exhaustion (Blackburn et al., 2008; Gehring 
et al., 2009) and PD-1 expression is not always associated with 
exhausted phenotype (Petrovas et al., 2006; Fourcade et al., 
2009), indicating that other molecules are likely involved in 
T cell exhaustion.
A recent study in patients with HIV has shown that the im-
mune regulator T cell immunoglobulin mucin (TIM) 3 is up-
regulated on exhausted CD8+ T cells (Jones et al., 2008). Tim-3   
is a molecule originally identified as being selectively expressed 
on IFN-–secreting Th1 and Tc1 cells (Monney et al., 2002).   
Interaction of Tim-3 with its ligand, galectin-9, triggers cell 
death in Tim-3+ T cells. Thus, both Tim-3 and PD-1 can func-
tion as negative regulators of T cell responses. In HIV patients, 
Figure 1.  PD-1 and Tim-3 expression in TILs. BALB/c mice were implanted with CT26 colon adenocarcinoma or 4T1 mammary adenocarcinoma. 
C57BL/6 mice were implanted with B16F10 melanoma. TILs were harvested and stained with 7AAD to exclude dead cells and antibodies against CD8, CD4, 
Tim-3, and PD-1. (A) Expression of Tim-3 and PD-1 on gated CD4+ and CD8+ TILs from a BALB/c mouse bearing CT26 tumor. FMO, fluorescence minus one 
controls for Tim-3 and PD-1 staining. Data shown are representative of more than five independent analyses. (B) Frequency of CD8+ cells in TILs express-
ing Tim-3 and PD-1 from tumor-bearing mice. The horizontal bars indicate means. *, P < 0.001; **, P < 0.05, one-way ANOVA followed by Tukey’s multiple 
comparison test. CT26 (n = 5), 4T1 (n = 6), and B16 (n = 9). (C) Frequency of CD8+Tim-3+ cells in spleens of tumor-bearing mice compared with spleens of 
naive tumor-free mice. The horizontal bars indicate means. *, P < 0.001, one-way ANOVA, Tukey’s multiple comparison test; **, P = 0.0188, unpaired  
Student’s t test. BALB/c, n = 11; CT26, n = 8; 4T1, n = 7; C57BL/6, n = 5; B16, n = 10.JEM VOL. 207, September 27, 2010 
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other cancers, we examined the CD8+ TILs in mice 
bearing other solid tumors: 4T1 mammary adeno-
carcinoma and B16F10 melanoma. Consistent with 
our observations in mice bearing CT26, cells that 
coexpress Tim-3 and PD-1 also comprise 50% of 
the CD8+ TILs in mice bearing 4T1 tumor, with 
cells expressing PD-1 alone or neither Tim-3 nor 
PD-1 also comprising smaller populations (25 and 
15%, respectively; Fig. 1 B). In mice bearing B16F10 
melanoma,  all  three  populations  of  CD8+  TILs   
(Tim-3PD-1, Tim-3PD-1+, and Tim-3+PD-1+)   
are present at roughly equal frequency. Interest-
ingly, in all three of the tumor models examined we 
did not observe any Tim-3+PD-1 TILs (Fig. 1 A 
and not depicted). We also examined CD4+ TILs; 
however, these are less abundant, and among these 
we  found  that  the  majority  were  Tim-3-PD-1 
with the Tim-3+PD-1+ and Tim-3PD-1+ popula-
tions being roughly equivalent (Fig. 1 A and not 
depicted).  Collectively,  these  data  indicate  that 
Tim-3 and PD-1 coexpressing CD8+ TILs com-
prise a major population of T cell present in TILs 
infiltrating different solid tumors.
We also examined Tim-3 and PD-1 expression 
in the spleens of tumor-bearing mice. Here, we   
observed a trend toward increased frequency of 
CD8+Tim-3+ cells compared with naive mice; however, the ex-
tent of this increase was variable among mice bearing different 
solid tumors (Fig. 1 C). In contrast to the CD8+ TILs, we found 
little if any evidence for coexpression of PD-1 with Tim-3 
among splenic CD8+ T cells in tumor-bearing mice (Fig. S1),   
suggesting that up-regulation of PD-1 on CD8+ Tim-3+ cells 
may happen in the tumor environment in response to environ-
mental cues. However, we could distinguish two distinct popu-
lations of Tim-3+ cells, Tim-3high and Tim-3low, in the peripheral 
lymphoid tissue of tumor-bearing mice. Similarly, among 
splenic CD4+ T cells in tumor-bearing mice, we observed a 
Tim-3high and Tim-3low population. Interestingly, the Tim-3low 
population was characterized by coexpression of PD-1, suggest-
ing that these cells may be the precursors of Tim-3+PD-1+ TILs 
and that they may represent T cells that are in a different func-
tional state from Tim-3high cells (Fig. S1).
(TILs) in mice bearing solid tumors. TILs that coexpress Tim-3 
and PD-1 predominate among CD8+ TILs and exhibit the 
most profound defects in T cell effector function. We further 
show that combined targeting of the Tim-3 and PD-1 path-
ways is highly effective in controlling tumor growth.
RESULTS
Tim-3 and PD-1 co expression on T cells in cancer
To examine a potential role for Tim-3 in T cell exhaustion in 
cancer, we first examined the expression of Tim-3 as well as 
PD-1 in T cells from mice bearing the solid tumor CT26 colon 
carcinoma. We observed that among CD8+ TILs, cells that 
coexpress Tim-3 and PD-1 comprise the major population 
(50%) with cells expressing PD-1 alone or neither Tim-3 
nor PD-1 comprising smaller populations (30% and 20%, 
respectively; Fig. 1, A and B). To extend these observations to 
Figure 2.  CD44 and CD62L expression in Tim-3– and 
PD-1–expressing TILs. TILs were harvested from CT26 tumor-
bearing mice and stained with 7AAD to exclude dead cells  
and antibodies against CD8, CD44, CD62L, Tim-3, and PD-1.  
(A) Representative staining on CD8+ Tim-3PD-1, Tim-3 
PD-1+, and Tim-3+PD-1+ TILs is shown. FMO, controls for CD44 
and CD62L staining are shown. Data are representative of 
three independent analyses. (B) Summary data showing the 
frequency of effector/memory (CD44hiCD62Llow) and central 
memory (CD44hiCD62Lhi) and CD44int cells within the CD8+ 
Tim-3PD-1, Tim-3PD-1+, and Tim-3+PD-1+ TILs. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001, one-way ANOVA and Tukey’s mul-
tiple comparison test. n = 3. Error bars represent SEM.2190 Targeting Tim-3 and PD-1 for anti-tumor immunity | Sakuishi et al.
(Barber et al., 2006). Furthermore, it has been observed that 
there is a hierarchy of  T cell exhaustion with CTL function 
and production of IL-2 being compromised first, followed by 
loss of  TNF and then IFN- (Wherry et al., 2003).  Therefore, 
to determine whether any of the Tim-3– and PD-1–expressing 
TILs exhibited exhausted phenotype, we isolated CD8+ TILs 
and examined their production of IL-2, TNF, and IFN- di-
rectly ex vivo. We found that the Tim-3+PD-1+ TILs exhib-
ited the most profound impairment in production of IL-2, 
TNF, and IFN- when compared with Tim-3PD-1+ TILs and 
Tim-3PD-1 TILs (Fig. 3 A). Surprisingly, the Tim-3PD-1+ 
TILs produced the most IFN- among the three populations 
of TILs and showed significantly less impairment in the pro-
duction of IL-2 and TNF than the Tim-3+PD-1+ TILs. These 
data suggest that the Tim-3+PD-1+ TILs represent the most ex-
hausted TILs and that Tim-3PD-1+ TILs may contain a mixture 
of exhausted T cells and effector T cells. To further confirm these 
observations, we determined the abundance of Tim-3+PD-1+ 
cells and Tim-3PD-1+ cells within the cytokine-producing 
and -nonproducing TILs (Fig. 3 B). We found that Tim-3+PD-1+ 
cells are the most abundant (55–60%) population among   
T cell dysfunction in TILs expressing Tim-3 and PD-1
To further characterize the different subsets of CD8+ TILs, we 
first examined their expression of CD44 and CD62L. We 
found that the pattern of CD62L and CD44 expression was 
quite different among the Tim-3PD-1, Tim-3PD-1+, and 
Tim-3+PD-1+ TILs (Fig. 2, A and B). Among the three popu-
lations, the Tim-3+PD-1+ population contained the largest 
fraction of effector/memory (CD44hiCD62Llow) cells but the 
lowest fraction of central memory (CD44hiCD62Lhi) cells. 
Indeed, the majority of Tim-3+PD-1+ TILs were CD62Llow. 
The majority of  TILs in all three populations expressed low   
to intermediate levels of CD44. Although this CD44int popula-
tion may comprise some naive cells, it is more likely that this 
population comprises cells that are transitioning from naive   
to effector status. The CD44int population was lowest among 
Tim-3+PD-1+ cells. These data gave the first indication that 
the three populations of TILs characterized by differential   
expression of  Tim-3 and PD-1 contain cells in different func-
tional states.
In  chronic  viral  infection,  PD-1  has  been  identified   
as a marker of dysfunctional or exhausted CD8+ T cells   
Figure 3.  Cytokine production in TILs from CT26 tumor-bearing mice. TILs were harvested from CT26 tumor-bearing mice and stimulated with 
PMA and ionomycin before intracytoplasmic cytokine staining. (A) Expression of cytokine in Tim-3PD-1, Tim-3PD-1+, and Tim-3+PD-1+ CD8+ TILs. 
Data shown are representative of five independent analyses. FMO, fluorescence minus one (anti-cytokine antibody). (B) Frequency of Tim-3PD-1+ and 
Tim-3+PD-1+ cells among CD8+ cytokine-producing and -nonproducing TILs (n = 5). The horizontal bars indicate means. *, P < 0.0001; **, P = 0.0261,  
unpaired Student’s t test.JEM VOL. 207, September 27, 2010 
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examined the ability of TILs to proliferate directly ex vivo by 
determining expression of Ki-67, a nuclear protein expressed 
by cells which have entered into cell cycle. However, it has 
been noted that in individuals chronically infected with HIV, 
cells that are arrested in G1 can express Ki-67+ (Combadière 
et al., 2000). We therefore also examined DNA content by si-
multaneously staining with TO-PRO-3 iodide. By doing so, 
we can discern cells arrested in G1 from cells that have pro-
gressed to S, G2, and M phase. We isolated TILs and stimu-
lated  them  directly  ex  vivo  before  examination  of  Ki-67 
expression and DNA content. We then determined the abun-
dance of Tim-3+PD-1+ and Tim-3PD-1+ cells in G0, G1, and   
S-M phases of cell cycle (Fig. 4 A). We found that Tim-3+  PD-1+ 
cells are the most abundant population that is stuck in G0, 
outnumbering Tim-3PD-1+ cells by 5 to 1 (Fig. 4 B). Inter-
estingly, when we examined cells that have progressed to the 
G1 and S-M phases, we found that Tim-3+PD-1+ cells steadily 
decrease in number, whereas Tim-3PD-1+ cells steadily in-
crease with progression through cell cycle. Collectively, our 
data strongly support that coexpression of Tim-3 and PD-1 
marks the most exhausted population of TILs, which fail to 
proliferate and produce IL-2, TNF, and IFN-.
Effect of targeting the Tim-3 and PD-1 signaling  
pathways in cancer
Our observations, along with the previous demonstrations 
that blockade of either the PD-1 or Tim-3 (Jones et al., 2008; 
Golden-Mason et al., 2009) signaling pathways can improve 
T cell function in the context of chronic infections, raised the 
possibility that combined targeting of these two pathways 
may prove to be the most efficacious means to restore anti-
tumor immunity in vivo. Before commencing in vivo treat-
ments, we first confirmed the expression of the PD-1 and 
Tim-3 ligands (PD-L1 and galectin-9, respectively) on CT26 
tumor (Fig. S2). We then treated CT26 tumor-bearing mice 
with an anti–Tim-3 antibody, which was previously described 
cytokine-nonproducing TILs, outnumbering Tim-3PD-1+ 
cells by three- to fourfold. Examination of cytokine-producing 
TILs revealed that Tim-3+PD-1+ cells are less abundant than 
Tim-3PD-1+ among IL-2–producing TILs. A similar trend 
was observed with TNF, although this did not reach statistical 
significance.  Both  populations  were  equally  represented 
among  IFN-–producing TILs.  Interestingly,  this  stepwise 
loss in abundance of Tim-3+PD-1+ cells among cytokine-
producing TILs seems to follow the hierarchy of  T cell ex-
haustion, suggesting that exhaustion is likely a dynamic 
process in vivo and that Tim-3+PD-1+ cells may be the first 
to develop exhausted phenotype.
As stated in the previous paragraph, loss of the ability to 
proliferate in response to TCR stimulation is among the first 
effector functions lost in exhausted T cells. We therefore   
Figure 4.  Proliferation and cell cycle entry in TILs from CT26  
tumor-bearing mice. TILs were harvested from CT26 tumor-bearing mice 
and stimulated with 1 µg/ml of anti-CD3 before staining with antibodies 
against CD8, Tim-3, PD-1, and Ki-67 and TO-PRO-3–iodide. (A) Expression 
of Ki-67 and TO-PRO-3 staining in CD8+ TILs showing the different phases 
of the cell cycle: G0, G1, and S→M. Data shown are representative of six 
independent analyses. (B) Ratio of Tim-3+PD-1+ to Tim-3PD-1+ TILs  
(n = 6) in different phases of cell cycle. *, P < 0.05, one-way ANOVA and 
Tukey’s multiple comparison test. n = 6. Error bars represent SEM.
Figure 5.  Effect of targeting the Tim-3 and PD-1 signaling pathways on tumor growth. (A) 5 × 105 CT26 cells were implanted into wild-type 
BALB/c mice. Mice were then treated with anti-Tim-3, anti-PD-L1, anti-Tim-3 + anti-PD-L1, or control immunoglobulins (RatIgG1 + RatIgG2b). Error bars 
represent SEM. Two independent experiments are shown. Left, control (n = 5), anti–Tim-3 (n = 5), anti–PD-L1 (n = 6), and anti–Tim-3 + anti–PD-L1  
(n = 5). Right, control (n = 4), anti–Tim-3 (n = 5), anti–PD-L1 (n = 4), and anti–Tim-3 + anti–PD-L1 (n = 3). (B) Pooled data from the experiments shown in A.  
Error bars represent SEM. Left, *, P < 0.01 compared with control or anti–Tim-3 group. Right, *, P < 0.01 compared with control group and P < 0.05  
compared with anti–Tim-3 group, one-way ANOVA and Tukey’s multiple comparison test.2192 Targeting Tim-3 and PD-1 for anti-tumor immunity | Sakuishi et al.
treated with both anti–Tim-3 and anti–PD-L1 antibodies. 
Indeed, these data parallel closely what we have seen in our 
in vivo treatment experiments, where anti–Tim-3 or anti–
PD-L1 alone has a limited and/or variable effect on tumor 
growth (Fig. 5). We have also examined the effect of anti–
Tim-3 plus anti–PD-L1 treatment on peripheral T cell re-
sponses from tumor-bearing mice and found that, similar to   
the effects observed on TILs, both anti–Tim-3 and anti–PD-L1   
alone had a variable and often weaker effect on IFN- pro-
duction relative to the effect of anti–Tim-3 plus anti–PD-L1   
(Fig. S4). Collectively, our data support that combined target-
ing of the Tim-3 and PD-1 signaling pathways is highly effec-
tive in restoring anti-tumor immunity.
DISCUSSION
In this paper, we have examined the expression of the inhibi-
tory receptors Tim-3 and PD-1 on TILs in mice bearing 
solid tumors and found that CD8+ TILs that coexpress Tim-3 
and PD-1 not only represent the most abundant TIL popula-
tion in multiple solid tumors but also represent the most dys-
functional or exhausted population of TILs. We further show 
that single targeting of the Tim-3 and PD-1 pathways has 
variable effects on tumor growth, whereas combined target-
ing of these pathways is highly effective in controlling tumor 
growth and restoring T cell production of IFN-. Similarly, 
a recent study has found that simultaneous targeting of the 
Tim-3 and PD-1 pathways also rescues CD8+ T cells from 
exhaustion in a model of chronic infection (Takamura et al., 
2010). Together, these findings support combined targeting 
of the Tim-3 and PD-1 pathways as an effective treatment 
not only for cancer but also for other chronic immune condi-
tions where T cell exhaustion is known to occur.
Until recently, PD-1 has been the primary marker for ex-
hausted T cells. However, our data show that PD-1 single-
positive TILs likely include bona fide effector T cells that   
produce IFN-, as this population contains the highest fre-
quency of IFN-–producing cells, even higher than the PD-1 
Tim-3 TILs (Fig. 3 A). Thus, our data suggest that PD-1   
is an imperfect marker of exhaustion and that coexpression of 
Tim-3 clearly marks the T cells with the most exhausted 
phenotype. However, several questions remain. It is known 
that triggering of Tim-3 can transmit a death signal into T cells. 
How then do Tim-3+PD-1+ exhausted T cells persist in 
chronic conditions? One possibility is that differential levels 
of Tim-3 expression drive different functional outcomes; i.e., 
high levels of Tim-3 promote T cell death whereas low levels 
of Tim-3 transmit an inhibitory signal that allows for cells to 
escape death and persist in a dysfunctional state. In this re-
gard, we have observed the presence of Tim-3low cells in both 
the CD4 and CD8 compartments in the periphery of tumor-
bearing mice (Fig. S1). It will be intriguing to determine if 
these T cells are in a different state of effector function com-
pared with Tim-3high cells. A second possibility is that coex-
pression of PD-1 and/or other inhibitory molecules, such as 
LAG-3,  is  responsible  for  preserving  cells  with  exhausted 
phenotype. Lastly, the decision between exhaustion and 
to have blocking function in vivo (Monney et al., 2002), anti-
PD-L1 antibody, anti–Tim-3 plus anti–PD-L1 antibodies, or 
control  immunoglobulins.  We  found  that  treatment  with 
anti–Tim-3 alone had little or no effect and treatment with 
anti–PD-L1  alone  showed  a  trend  toward  delayed  tumor 
growth, but this varied between experiments and did not 
reach  statistical  significance  (Fig.  5).  However,  combined 
treatment with anti–Tim-3 and anti–PD-L1 resulted in a dra-
matic reduction in tumor growth, with 50% of the mice ex-
hibiting complete tumor regression. Indeed, the mice from 
the combined anti–Tim-3 plus anti–PD-L1 group that ex-
hibited complete regression remained tumor free even after 
rechallenge  (unpublished  data).  Because  CT26  tumor  ex-
presses PD-L1 but not Tim-3 (Fig. S2), we controlled for the 
possibility that anti–PD-L1 antibody could have direct in-
hibitory effects on tumor growth. We cultured CT26 tumor 
in the presence of anti–PD-L1 or control immunoglobulin 
and found that tumor proliferation was not affected (Fig. S3). 
We have also tested the effect of anti–Tim-3 plus anti–PD-L1   
treatment in mice bearing B16 melanoma and found that mice 
receiving the combined treatment exhibit enhanced survival 
relative to control immunoglobulin, anti–Tim-3, or anti–PD-L1– 
treated mice (unpublished data).
To address directly whether treatment with anti–Tim-3 
plus anti–PD-L1 indeed restores TILs function, we isolated 
TILs from mice bearing CT26 tumor and cultured them in 
the presence of anti–Tim-3, anti–PD-L1, anti–Tim-3 plus 
anti–PD-L1 antibodies, or control immunoglobulins (Fig. 6). 
We found that although both anti–Tim-3 and anti–PD-L1 
alone were able to augment IFN- production from TILs, 
this effect was variable and often weaker when compared 
with  the  increase  in  IFN-  production  observed  in  TILs 
Figure 6.  Blockade of the Tim-3 and PD-1 signaling pathways 
restores IFN- production. TILs were harvested from CT26 tumor- 
bearing mice and cultured in vitro in the presence of soluble anti-CD3 
and anti–Tim-3, anti–PD-L1, anti–Tim-3 plus anti–PD-L1, or control im-
munoglobulins. After 96 h, culture supernatant was collected and IFN- 
measured by cytometric bead array. Data are expressed as the difference 
in cytokine production over that observed in cultures with control immuno-
globulins. Data shown are from three independent TILs samples from two 
independent experiments.JEM VOL. 207, September 27, 2010 
Article
2193
10F.9G2) on days 0, 3, 6, 9, and 12, or isotype control immunoglobulins 
(Rat IgG1 and RatIgG2b). Tumor surface was measured in two dimensions 
using a caliper.
In vitro experiments. TILs were harvested as described and cultured (1–3 × 
105/well) in the presence of 5 µg/ml of soluble anti-CD3 and 10 µg/ml of 
anti–Tim-3  (clone  8B.2C12),  anti–PD-L1  (clone  10F.9G2),  anti–Tim-3 
plus anti–PD-L1, or control immunoglobulins (rat IgG1 and rat IgG2b).   
After 96 h, culture supernatant was collected and IFN- measured by cyto-
metric bead array (BD).
Online supplemental material. Fig. S1 shows the Tim-3 and PD-1 ex-
pression on CD8 and CD4 cells in the spleen of tumor-bearing mice. Fig. S2 
shows the expression of PD-L1, Tim-3, and Galectin-9 on CT26 tumor 
cells. Fig. S3 shows the effects of anti–PD-L1 antibody on the growth of 
CT26 tumor in vitro. Fig. S4 shows the effect of in vivo targeting of the 
Tim-3 and PD-1 signaling pathways in tumor-bearing mice on peripheral   
T cell responses. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20100637/DC1.
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